Ulcerative Colitis (UC)Phase 3COMMANDNCT03398135
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
A Phase 3 study testing risankizumab in people with Ulcerative Colitis (UC), run by AbbVie at 426 sites in 43 countries.
Trial summary
The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC. Read more about this study
- Who is it for?
- Ages 16 to 80 years
- Conditions the study is for
- Ulcerative Colitis (UC)
- What is being tested?
- risankizumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,242 participants
- Where
- 426 sitesin 43 countries
- Study dates
- 28 Aug 2018to Feb 2029
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 80 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Participants who have completed Study M16-067 and have achieved clinical response as defined in the protocol.
Who cannot join
- Participants who have a known hypersensitivity to risankizumab or the excipients of any of the study drugs or the ingredients of chinese hamster ovary (CHO) or had an adverse event (AE) during Studies M16-067 that in the Investigator's judgment makes the participant unsuitable for this study.
- Participant is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
- Participant is not in compliance with prior and concomitant medication requirements throughout Studies M16-067.
Trial locations and contacts
426 sites in 43 countries.
426 sites in 43 countries
United States78 sites
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 159430
Ann Arbor, Michigan, 48109
Inquest Clinical Research /ID# 165686
Baytown, Texas, 77521-2415
Massachusetts General Hospital - Crohn's and Colitis Center /ID# 164257
Boston, Massachusetts, 02114
Texas Digestive Disease Consultants /ID# 209951
Cedar Park, Texas, 78613-5028
GI Alliance /ID# 209799
Cedar Park, Texas, 78613
Atrium Health Carolinas Medical Center /ID# 158543
Charlotte, North Carolina, 28203
Clin Res Inst of Michigan, LLC /ID# 160300
Chesterfield, Michigan, 48047
The University of Chicago Medical Center /ID# 160511
Chicago, Illinois, 60637-1443
South Lake Pain Institute, Inc /ID# 162859
Clermont, Florida, 34711
Cleveland Clinic Main Campus /ID# 209235
Cleveland, Ohio, 44195
Peak Gastroenterology Associates, PC /ID# 165838
Colorado Springs, Colorado, 80907
The Ohio State University /ID# 164713
Columbus, Ohio, 43210
Optimed Research, Ltd. /ID# 167112
Columbus, Ohio, 43235
Gastro One /ID# 160373
Cordova, Tennessee, 38018
Southern California Res. Ctr. /ID# 169659
Coronado, California, 92118-1408
Plains Clinical Research Center, LLC /ID# 169729
Fargo, North Dakota, 58104-5925
Digestive Health Associates of Texas (DHAT) Research Institute - Garland /ID# 158235
Garland, Texas, 75044
Gastroenterology Associates, P.A. of Greenville /ID# 160457
Greenville, South Carolina, 29607
Duplicate_Medical Research Center of CT /ID# 160287
Hamden, Connecticut, 06518
Penn State Milton S. Hershey Medical Center /ID# 230474
Hershey, Pennsylvania, 17033-2360
Houma Digestive Health Special /ID# 158377
Houma, Louisiana, 70360
Vilo Research Group Inc /ID# 207657
Houston, Texas, 77017-2337
Baylor College of Medicine /ID# 158230
Houston, Texas, 77030
Centex Studies, Inc. - Houston /ID# 201221
Houston, Texas, 77058
Indiana University /ID# 167250
Indianapolis, Indiana, 46202
Hoag Memorial Hosp Presbyterian /ID# 218347
Irvine, California, 92618
Duplicate_East Tennessee Research Institute /ID# 168744
Johnson City, Tennessee, 37604
Univ Kansas Med Ctr /ID# 226601
Kansas City, Kansas, 66160
UC San Diego Health System /ID# 160430
La Jolla, California, 92037
Rocky Mountain Pediatric Gastroenterology /ID# 207173
Lone Tree, Colorado, 80124-6798
United Medical Doctors /ID# 158574
Los Alamitos, California, 90720-3309
Cedars-Sinai Medical Center /ID# 163848
Los Angeles, California, 90048
Gastrointestinal Biosciences Clinical Trials, LLC /ID# 200934
Los Angeles, California, 90067-2001
Duplicate_Robley Rex VA Medical Center /ID# 218647
Louisville, Kentucky, 40206
Duplicate_Caprock Gastro Research, LLC /ID# 215433
Lubbock, Texas, 79424-3017
Gastroenterology Associates of Central Georgia, LLC /ID# 160513
Macon, Georgia, 31201
Ctr for Advanced Gastroenterol /ID# 202820
Maitland, Florida, 32751-6108
Great Lakes Gastroenterology Research, LLC /ID# 201778
Mentor, Ohio, 44060-6211
University of Miami /ID# 160456
Miami, Florida, 33136
Coral Research Clinic /ID# 158608
Miami, Florida, 33186-4643
South Florida Research Ph I-IV, Inc. /ID# 161844
Miami, Florida, 33193
Gastroenterology Group Naples /ID# 165210
Naples, Florida, 34102
Vanderbilt University Medical Center /ID# 160567
Nashville, Tennessee, 37232-0011
Yale Univ Digestive Diseases /ID# 213265
New Haven, Connecticut, 06510
Delricht Research /ID# 206817
New Orleans, Louisiana, 70115
Nola Research Works, LLC /ID# 161356
New Orleans, Louisiana, 70115
Advanced Research Institute, Inc /ID# 161945
New Port Richey, Florida, 34653
Weill Cornell Medicine /ID# 165884
New York, New York, 10022
Columbia Univ Medical Center /ID# 161929
New York, New York, 10032-3725
Lenox Hill Hospital /ID# 168469
New York, New York, 10075
Manhattan Clinical Research, LLC /ID# 211803
New York, New York, 10279
Duplicate_DiGiovanna Institute for Medical Education & Research /ID# 171128
North Massapequa, New York, 11758
DM Clinical Research/Southwest /ID# 165009
Oak Lawn, Illinois, 60453
Advanced Research Institute /ID# 160465
Ogden, Utah, 84405
Digestive Disease Specialists /ID# 170777
Oklahoma City, Oklahoma, 73112
Quality Clinical Research Inc. /ID# 167312
Omaha, Nebraska, 68114-3723
Advent Health /ID# 160393
Orlando, Florida, 32803
Endoscopic Research, Inc. /ID# 206709
Orlando, Florida, 32803
Omega Research Group /ID# 203105
Orlando, Florida, 32808
University of Pennsylvania /ID# 166262
Philadelphia, Pennsylvania, 19104-5502
Gastroenterology Consultants of Southwest Virginia /ID# 218142
Roanoke, Virginia, 24014-1372
Mayo Clinic - Rochester /ID# 200455
Rochester, Minnesota, 55905-0001
Duplicate_University of Rochester Medical Center /ID# 161660
Rochester, New York, 14642
Clinical Associates in Research Therapeutics of America, LLC /ID# 161364
San Antonio, Texas, 78212
Southern Star Research Institute, LLC /ID# 168774
San Antonio, Texas, 78229-5390
UCSF Medical Center - Mount Zion /ID# 201209
San Francisco, California, 94115
Virginia Mason Hospital & Medical Center /ID# 160432
Seattle, Washington, 98101
Louisiana Research Center, LLC /ID# 201205
Shreveport, Louisiana, 71105-6800
Duplicate_Lenus Research & Medical Group /ID# 169727
Sweetwater, Florida, 33172
ProMedica Physicians Digestive Healthcare /ID# 215622
Sylvania, Ohio, 43560-2767
Clinical Research Trials of Florida, Inc. /ID# 201794
Tampa, Florida, 33607
Duplicate_AdventHealth Tampa /ID# 170482
Tampa, Florida, 33613-4680
Baylor Scott & White Center for Diagnostic Medicine /ID# 204132
Temple, Texas, 76508
Cotton O'Neil Clinical Research Center, Digestive Health /ID# 160367
Topeka, Kansas, 66606
Adult Gastroenterology Associates - Gen 1 Research /ID# 208873
Tulsa, Oklahoma, 74136-7823
Tyler Research Institute, LLC /ID# 166799
Tyler, Texas, 75701
Gastro Health & Nutrition - Victoria /ID# 164308
Victoria, Texas, 77904
Digestive Disease Associates, LTD - Wyomissing /ID# 232406
Wyomissing, Pennsylvania, 19610
Japan61 sites
Tokatsu Tsujinaka Hospital /ID# 164310
Abiko-shi, Chiba, 270-1168
Duplicate_Asahikawa Medical University Hospital /ID# 164324
Asahikawa-shi, Hokkaido, 078-8510
Institute of Science Tokyo Hospital /ID# 164225
Bunkyo-ku, Tokyo, 113-8519
Chiba University Hospital /ID# 209633
Chiba, Chiba, 260-8677
Fukuoka University Chikushi Hospital /ID# 209056
Chikushino-shi, Fukuoka, 818-8502
St. Lukes International Hospital /ID# 225969
Chuo-ku, Tokyo, 104-8560
Saiseikai Fukuoka Genaral Hospital /ID# 225640
Fukuoka, Fukuoka, 810-0001
Fukuoka University Hospital /ID# 226723
Fukuoka, Fukuoka, 814-0180
National Hospital Organization Fukuyama Medical Center /ID# 164315
Fukuyama-shi, Hiroshima, 720-8520
Gifu University Hospital /ID# 208490
Gifu, Gifu, 501-1194
Tokai University Hachioji Hospital /ID# 227102
Hachioji-shi, Tokyo, 192-0032
Hamamatsu University Hospital /ID# 226729
Hamamatsu, Shizuoka, 431-3192
Matsuda Hospital - Hamamatsu /ID# 226831
Hamamatsu, Shizuoka, 432-8061
National Hospital Organization Hirosaki General Medical Center /ID# 164216
Hirosaki-shi, Aomori, 036-8545
Hiroshima University Hospital /ID# 164240
Hiroshima, Hiroshima, 734-8551
Tokai University Hospital /ID# 209207
Isehara, Kanagawa, 259-1193
Sameshima Hospital /ID# 211182
Kagoshima, Kagoshima-ken, 892-0846
Gokeikai Ofuna Chuo Hospital /ID# 169296
Kamakura-shi, Kanagawa, 247-0056
Kanazawa University Hospital /ID# 169221
Kanazawa, Ishikawa-ken, 920-8641
Nara Medical University Hospital /ID# 169222
Kashihara-shi, Nara, 634-8522
Tsujinaka Hospital - Kashiwanoha /ID# 225968
Kashiwa-shi, Chiba, 277-0871
St Marianna University School Of Medicine /ID# 226730
Kawasaki-shi, Kanagawa, 216-8511
Aoyama Clinic /ID# 164236
Kobe, Hyōgo, 650-0015
Kurume University Hospital /ID# 164237
Kurume-shi, Fukuoka, 830-0011
Kitasato University Kitasato Institute Hospital /ID# 164222
Minato-ku, Tokyo, 108-8642
Kyorin University Hospital /ID# 164226
Mitaka-shi, Tokyo, 181-8611
Aichi Medical University Hospital /ID# 164227
Nagakute, Aichi-ken, 480-1195
Duplicate_Nagasaki University Hospital /ID# 205326
Nagasaki, Nagasaki, 852-8501
Daido Clinic - Nagoya /ID# 211478
Nagoya, Aichi-ken, 457-8511
Duplicate_Nagoya University Hospital /ID# 164230
Nagoya, Aichi-ken, 4668560
Nagoya City University Hospital /ID# 164229
Nagoya, Aichi-ken, 467-8602
Hyogo Medical University Hospital /ID# 164238
Nishinomiya-shi, Hyōgo, 663-8501
Ogaki Municipal Hospital /ID# 226009
Ogaki-shi, Gifu, 503-8502
Kinshukai Infusion Clinic /ID# 226992
Osaka, Osaka, 530-0011
Shiga University of Medical Science Hospital /ID# 164323
Ōtsu, Shiga, 520-2192
Saga University Hospital /ID# 209273
Saga, Saga-ken, 849-8501
Kitasato University Hospital /ID# 169223
Sagamihara-shi, Kanagawa, 252-0375
Tokitokai Tokito clinic /ID# 164218
Saitama-shi, Saitama, 336-0963
Toho University Sakura Medical Center /ID# 164219
Sakura-shi, Chiba, 285-8741
Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 164215
Sapporo, Hokkaido, 060-0033
Sapporo Medical University Hospital /ID# 164278
Sapporo, Hokkaido, 060-8543
Sapporo IBD Clinic /ID# 225967
Sapporo, Hokkaido, 064-0919
Sapporo Higashi Tokushukai Hospital /ID# 208493
Sapporo, Hokkaido, 065-0033
Tohoku University Hospital /ID# 164276
Sendai, Miyagi, 9808574
NTT Medical Center Tokyo /ID# 225595
Shinagawa-ku, Tokyo, 141-8625
Keio University Hospital /ID# 203630
Shinjuku-ku, Tokyo, 160-8582
Tokuyama Central Hospital /ID# 226857
Shunan-shi, Yamaguchi, 745-8522
NHO Shizuoka Medical Center /ID# 164314
Sunto-gun, Shizuoka, 411-8611
National Hospital Organization Takasaki General Medical Center /ID# 164312
Takasaki-shi, Gunma, 370-0829
Osaka Medical and Pharmaceutical University Hospital /ID# 226036
Takatsuki-shi, Osaka, 569-8686
The Jikei University Hospital /ID# 164279
Tokyo, 105-8461
Teikyo University Hospital /ID# 225594
Tokyo, 173-8605
Fujita Health University Hospital /ID# 164313
Toyoake, Aichi-ken, 470-1192
Mie University Hospital /ID# 203635
Tsu, Mie-ken, 514-8507
Japanese Red Cross Wakayama Medical Center /ID# 171196
Wakayama, Wakayama, 640-8558
Wakayama Medical University Hospital /ID# 169485
Wakayama, Wakayama, 641-8510
Yamagata University Hospital /ID# 171481
Yamagata, Yamagata, 990-9585
Yokkaichi Hazu Medical Center /ID# 164316
Yokkaichi-shi, Mie-ken, 510-0016
Matsushima Hospital /ID# 254448
Yokohama, Kanagawa, 220-0041
Colo-proctology Center Matsushima Clinic /ID# 225915
Yokohama, Kanagawa, 220-0045
SHOWA Medical University Fujigaoka Hospital /ID# 209606
Yokohama, Kanagawa, 227-8501
China25 sites
Beijing Friendship Hospital /ID# 211061
Beijing, Beijing Municipality, 100032
The First Hospital of Jilin University /ID# 212277
Changchun, Jilin, 130021
The Second Xiangya Hospital Of Central South University /ID# 211196
Changsha, Hunan, 410011
West China Hospital, Sichuan University /ID# 211275
Chengdu, Sichuan, 610041
The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 211229
Guangzhou, Guangdong, 510655
The Second Affiliated Hospital of Zhejiang University School of Medicine /ID# 211024
Hangzhou, Zhejiang, 310009
Sir Run Run Shaw Hospital,Meical School Zhejiang University /ID# 211062
Hangzhou, Zhejiang, 310018
The First Affiliated Hospital of Anhui Medical University /ID# 211227
Hefei, Anhui, 230022
Huai'an First People's Hospital /ID# 239197
Huaian, Jiangsu, 223399
The First Affiliated Hospital of Nanchang University /ID# 212182
Nanchang, Jiangxi, 330006
Nanjing Drum Tower Hospital /ID# 227438
Nanjing, Jiangsu, 210008
Jiangsu Province Hospital /ID# 211234
Nanjing, Jiangsu, 210029
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 210960
Shanghai, Shanghai Municipality, 200065
Renji Hospital, Shanghai Jiaotong University School of Medicine /ID# 211230
Shanghai, Shanghai Municipality, 200127
Shanghai East Hospital /ID# 218796
Shanghai, Shanghai Municipality, 200136
Shanghai General Hospital /ID# 226652
Shanghai, Shanghai Municipality, 201600
Shengjing Hospital of China Medical University /ID# 211643
Shenyang, Liaoning, 110022
The Second Hospital of Hebei Medical University /ID# 213019
Shijiazhuang, Hebei, 050000
Tongji Hospital Tongji Medical College of HUST /ID# 211069
Wuhan, Hubei, 430030
Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 211070
Wuhan, Hubei, 430048
Renmin Hospital of Wuhan University /ID# 212867
Wuhan, Hubei, 430060
Wuxi People's Hospital /ID# 218797
Wuxi, Jiangsu, 214023
Xijing Hospital /ID# 210708
Xi'an, Shaanxi, 710032
Tangdu Hospital of The Fourth Military Medical University, PLA /ID# 215505
Xi’an, Shanxi, 710038
General Hospital of Ningxia Medical University /ID# 213912
Yinchuan, Ningxia, 750000
Germany20 sites
Gastroenterologische Spezialpraxis am Wittenbergplatz /ID# 219146
Berlin, 10787
MVZ fuer Gastroenterlogie am Bayerischen Platz /ID# 159380
Berlin, 10825
Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 210508
Berlin, 12203
DRK Kliniken Berlin Westend /ID# 166155
Berlin, 14050
Stadtisches Klinikum Braunschweig /ID# 163694
Braunschweig, 38126
Universitaetsklinikum Koeln /ID# 164993
Cologne, North Rhine-Westphalia, 50937
Universitaetsklinikum Erlangen /ID# 159373
Erlangen, Bavaria, 91054
Duplicate_Agaplesion Markus Krankenhaus /ID# 159375
Frankfurt am Main, Hesse, 60431
Universitaetsklinikum Freiburg /ID# 162038
Freiburg im Breisgau, Baden-Wurttemberg, 79106
Praxiszentrum fuer Gastroenterologie /ID# 219072
Grevenbroich, North Rhine-Westphalia, 41515
Praxis fuer Gastroenterologie /ID# 166154
Heidelberg, Baden-Wurttemberg, 69121
Gastroenterologie Opernstrasse Private Practice - Dr. Falk & Krause & Kuhn /ID# 163690
Kassel, Hesse, 34117
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 159379
Kiel, Schleswig-Holstein, 24105
Eugastro /ID# 219071
Leipzig, Saxony, 04103
Klinikum Lueneburg /ID# 163692
Lüneburg, Lower Saxony, 21339
Universitatsklinikum Mannheim /ID# 162039
Mannheim, Baden-Wurttemberg, 68167
Gastroenterologische Gemeinschaftspraxis Minden /ID# 162037
Minden, North Rhine-Westphalia, 32423
Duplicate_LMU Klinikum Campus Grosshadern /ID# 210484
Munich, Bavaria, 81377
Universitaetsklinikum Regensburg /ID# 163693
Regensburg, 93042
Universitaetsklinikum Ulm /ID# 164994
Ulm, Baden-Wurttemberg, 89081
Russia17 sites
Interdisctrict Multidisciplinary Hospital /ID# 204921
Anzorey, Kabardino-Balkarskaya Respublika, 361350
Clinic of New Technologies of Medicine /ID# 204926
Dzerzhinskiy, 140091
Immanuel Kant Baltic Federal University /ID# 204920
Kaliningrad, Kaliningrad Oblast, 236016
Kuzbass Regional Clinical Hospital /ID# 165759
Kemerovo, Kemerovo Oblast, 650099
Arsvita Clinic /ID# 208947
Korolyov, Moscow Oblast, 141077
First Moscow State Medical University n.a I.M. Sechenov /ID# 204981
Moscow, 119992
National Medical Research Center of Coloproctology n.a. A. N. Ryzhikh /ID# 203513
Moscow, 123423
Central Clinical Hospital RZHD Medicine /ID# 204922
Moscow, 129128
GBUZ Allergology and Immunology Center of Ministry of Health of Kabardino-Bal /ID# 233974
Nal'chik, Kabardino-Balkarskaya Respublika, 360001
Novosibirski Gastrocenter /ID# 229852
Novosibirsk, Novosibirsk Oblast, 630007
Perm Clinical Center of the Federal Medical and Biological Agency /ID# 227456
Perm, Permskiy Kray, 614109
Euromedservice /ID# 204918
Pushkin, 196603
Uninova Medical Center /ID# 229786
Saint Petersburg, Leningradskaya Oblast', 198218
International Medical Center SOGAZ /ID# 206832
Saint Petersburg, 191186
City Clinical Hospital #40 /ID# 204927
Sestroretsk, Sankt-Peterburg, 197706
Regional Clinical Hospital #1 /ID# 165763
Tyumen, Tyumen Oblast, 625023
Ulyanovsk Regional Clinical Hospital /ID# 204923
Ulyanovsk, 432017
Italy15 sites
IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 155627
Bologna, 40138
Ospedale Cannizzaro /ID# 164039
Catania, 95126
Azienda Ospedaliero-Universitaria Renato Dulbecco /ID# 200124
Catanzaro, 88100
Ospedale San Martino /ID# 164030
Genoa, Genova, 16132
ASST Fatebenefratelli Sacco /ID# 155623
Milan, Milano, 20157
ASST Grande Ospedale Metropolitano Niguarda /ID# 170959
Milan, Milano, 20162
Azienda Ospedaliero-Universitaria di Modena /ID# 201818
Modena, 41124
IRCCS Ospedale Sacro Cuore Don Calabria /ID# 164029
Negrar, Verona, 37024
ASST Rhodense/Presidio Ospedaliero di Rho /ID# 211450
Rho, Milano, 20017
Fondazione Policlinico Universitario Campus Bio-Medico /ID# 163994
Roma, 00128
Azienda Ospedaliera Universitaria Policlinico Tor Vergata /ID# 158020
Rome, Roma, 00133
Azienda Ospedaliera San Camillo Forlanini /ID# 155628
Rome, Roma, 00149
Duplicate_Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 171223
Rome, Roma, 00161
UOC Medicina Interna e Gastroe /ID# 155624
Rome, 00168
IRCCS Istituto Clinico Humanitas /ID# 155626
Rozzano, Lombardy, 20089
Poland12 sites
Vitamed Galaj i Cichomski Sp.j. /ID# 213358
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-079
NZOZ All-Medicus /ID# 170282
Katowice, Silesian Voivodeship, 40-659
Centrum Medyczne Plejady /ID# 170635
Krakow, Lesser Poland Voivodeship, 30-363
Endoskopia Sp. z o.o. /ID# 170284
Sopot, Pomeranian Voivodeship, 81-756
Gastromed Sp. z o.o /ID# 231065
Torun, Kuyavian-Pomeranian Voivodeship, 87-100
H-T Centrum Medyczne Endoterapia /ID# 231501
Tychy, Silesian Voivodeship, 43-100
Centrum Zdrowia MDM /ID# 170283
Warsaw, Masovian Voivodeship, 00-189
Medical Network Sp.z.o.o. WIP Warsaw IBD Point Profesor Kierkus /ID# 216103
Warsaw, Masovian Voivodeship, 00-728
Panstwowy Instytut Medyczny MSWiA w Warszawie /ID# 170286
Warsaw, Masovian Voivodeship, 02-507
Narodowy Instytut Onkologii im. Marii Sk?odowskiej-Curie Panstwowy Instytut Bada /ID# 170285
Warsaw, Masovian Voivodeship, 02-781
Vivamed Sp. z o.o. /ID# 216308
Warsaw, Masovian Voivodeship, 03-580
Vistamed /ID# 210106
Wroclaw, Lower Silesian Voivodeship, 53-149
Spain12 sites
Hospital Clinic de Barcelona /ID# 159462
Barcelona, 08036
Duplicate_Hospital Universitario Reina Sofia /ID# 167062
Córdoba, 14004
Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 159463
Ferrol, A Coruna, 15405
Hospital Universitario de Cabuenes /ID# 170745
Gijón, Principality of Asturias, 33394
Hospital Universitario La Paz /ID# 159471
Madrid, 28046
Hospital Universitario Puerta de Hierro - Majadahonda /ID# 159466
Majadahonda, Madrid, 28222
Complejo Hospitalario Universitario de Pontevedra /ID# 216183
Pontevedra, 36071
Consorci Corporacio Sanitaria Parc Tauli Sabadell /ID# 159473
Sabadell, Barcelona, 08208
Hospital Universitario de Salamanca /ID# 159469
Salamanca, 37711
Hospital Universitario Virgen Macarena /ID# 159969
Seville, 41009
Hospital Alvaro Cunqueiro CHUVI /ID# 167359
Vigo, Pontevedra, 36213
Hospital Universitario Miguel Servet /ID# 159468
Zaragoza, 50009
Canada11 sites
Duplicate_University of Calgary /ID# 169125
Calgary, Alberta, T2N 4Z6
Allen Whey Khye Lim Professional Corporation /ID# 169770
Edmonton, Alberta, T5R 1W2
Covenant Health /ID# 169128
Edmonton, Alberta, T6K 4B2
Hotel Dieu de Levis /ID# 214379
Lévis, Quebec, G6V 3Z1
London Health Sciences Center- University Hospital /ID# 169117
London, Ontario, N6A 5W9
CIUSSS de l'est de l'Ile-de-Montreal - Hopital Maisonneuve-Rosemont /ID# 169122
Montreal, Quebec, H1T 2M4
Montreal General Hospital- McGill University Health Center /ID# 169118
Montreal, Quebec, H3G 1A4
Fraser Clinical Trials Inc /ID# 169116
New Westminster, British Columbia, V3L 3W4
Scott Shulman Medicine Professional Corporation /ID# 169127
North Bay, Ontario, P1B 2H3
Toronto Digestive Disease Associates /ID# 169120
Vaughan, Ontario, L4L 4Y7
Percuro Clinical Research, Ltd /ID# 169123
Victoria, British Columbia, V8V 3M9
South Korea11 sites
Inje University Haeundae Hospital /ID# 203027
Busan, Busan Gwang Yeogsi, 48108
Dong-A University Medical Center /ID# 158665
Busan, Busan Gwang Yeogsi, 49201
Duplicate_Pusan National University Hospital /ID# 158670
Busan, Busan Gwang Yeogsi, 49241
Yeungnam University Medical Center /ID# 158662
Daegu, 42415
The Catholic University of Korea, Daejeon St. Mary's Hospital /ID# 242379
Daejeon, Daejeon Gwang Yeogsi, 34943
Duplicate_Hanyang University Gurihospital /ID# 158661
Guri-si, Gyeonggido, 11923
CHA Bundang Medical Center /ID# 158669
Seongnam, Gyeonggido, 13496
Kangbuk Samsung Hospital /ID# 158666
Seoul, Seoul Teugbyeolsi, 03181
Samsung Medical Center /ID# 158663
Seoul, Seoul Teugbyeolsi, 06351
Yonsei University Health System Severance Hospital /ID# 158660
Seoul, 03722
The Catholic University Of Korea St. Vincent's Hospital /ID# 158664
Suwon, Gyeonggido, 16247
France10 sites
Duplicate_CHU Amiens-Picardie Site Sud /ID# 207880
Amiens, Somme, 80054
Hopital Beaujon /ID# 207876
Clichy, Île-de-France Region, 92110
APHM - Hopital Nord /ID# 225826
Marseille, Bouches-du-Rhone, 13015
CHU Montpellier - Hopital Saint Eloi /ID# 223781
Montpellier, Herault, 34295
Clinique Jules Verne /ID# 240977
Nantes, 44300
Centre Medico Chirurgical Ambroise Pare Hartmann /ID# 249861
Neuilly-sur-Seine, Île-de-France Region, 92200
Chu de Nice-Hopital Larchet Ii /Id# 207881
Nice, Alpes-Maritimes, 06202
Centre Hospitalier Universitaire de Bordeaux /ID# 207883
Pessac, New Aquitaine, 33604
Duplicate_CHU de SAINT ETIENNE - Hopital Nord /ID# 207882
Saint Priest EN Jarez, Pays de la Loire Region, 42270
Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois /ID# 207877
Vandœuvre-lès-Nancy, Meurthe-et-Moselle, 54511
United Kingdom10 sites
Barnsley Hospital NHS Foundation Trust /ID# 202771
Barnsley, S75 2EP
Addenbrookes Hospital /ID# 158046
Cambridge, Cambridgeshire, CB2 2QQ
Western General Hospital - NHS Lothian /ID# 208801
Edinburgh, Edinburgh, City of, EH4 2XU
Royal Devon & Exeter Hospital /ID# 157614
Exeter, Devon, EX2 5DW
Liverpool University Hospitals NHS Foundation Trust /ID# 203860
Liverpool, L7 8XP
Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 157617
London, Greater London, E1 2ES
Kings College Hospital NHS Foundation Trust /ID# 158762
London, Greater London, SE5 9RS
St George University Hospitals NHS Foundation Trust /ID# 208379
London, Greater London, SW17 0QT
The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 158047
Newcastle upon Tyne, NE3 3HD
University Hospital Southampton NHS Foundation Trust /ID# 210814
Southampton, Hampshire, SO16 6YD
Turkey (Türkiye)9 sites
Ankara Univ Medical Faculty /ID# 167205
Ankara, 06590
Inonu Universitesi Turgut Ozal /ID# 203980
Battalgazi/malatya, 44280
Uludag University Medical Faculty /ID# 204179
Bursa, 16059
F?rat University Medical Facul /ID# 171285
Elâzığ, 23100
Istanbul Universitesi-Cerrahpasa Cerrahpasa Tip Fakultesi /ID# 167202
Istanbul, 34098
Duplicate_Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 171290
Istanbul, 34899
Acibadem Kozyatagi Hospital /ID# 213277
Kadıköy, Istanbul, 34742
Duplicate_Erciyes University Medical Fac /ID# 171283
Melikgazi, Kayseri, 38030
Sisli Etfal Train & Res Hosp /ID# 171415
Şişli, Istanbul, 34371
Belgium8 sites
Universite Libre de Bruxelles - Hopital Erasme /ID# 200256
Anderlecht, Brussels Capital, 1070
Imelda Ziekenhuis /ID# 211101
Bonheiden, Antwerpen, 2820
Cliniques Universitaires UCL Saint-Luc /ID# 200260
Brussels, Brussels Capital, 1200
Universitair Ziekenhuis Leuven /ID# 170829
Leuven, Vlaams-Brabant, 3000
Groupe Sante CHC - Clinique du MontLegia /ID# 200255
Liège, Liege, 4000
CHU de Liege /ID# 200257
Liège, 4000
AZ-Delta /ID# 200258
Roeselare, West-Vlaanderen, 8800
Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant /ID# 200259
Yvoir, Namur, 5530
Greece8 sites
General Hospital of Athens Ippokratio /ID# 229190
Athens, Attica, 11527
General Hospital of Athens Laiko /ID# 206438
Athens, Attica, 11527
General Hospital of Chest Diseases of Athens SOTIRIA /ID# 170910
Athens, Attica, 11527
General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 217479
Athens, 10676
University General Hospital of Heraklion PA.G.N.I /ID# 165327
Heraklion, Crete, 71500
General Hospital of Nikaia-Piraeus "Agios Panteleimon" /ID# 165313
Nikaia, Attica, 18454
Tzaneio general hospital of Piraeus /ID# 206437
Piraeus, Attica, 18536
Theageneio Anticancer Hospital /ID# 165329
Thessaloniki, 54639
Portugal8 sites
Duplicate_Hospital Garcia de Orta, EPE /ID# 165579
Almada, Setúbal District, 2805-267
Unidade Local de Saude de Coimbra, EPE /ID# 166050
Coimbra, 3000-075
Centro Hospitalar Do Alto Ave - Hospital Senhora Da Oliveira /ID# 165576
Guimarães, Braga District, 4839-008
Duplicate_Centro Hospitalar Universitario Lisboa Central, EPE - Hospital dos Cap /ID# 165578
Lisbon, 1169-050
Centro Hospitalar Universitário do Algarve, EPE - Hospital de Portimão /ID# 166563
Portimão, Faro District, 8500-338
Unidade Local de Saude Sao Joao, EPE /ID# 165577
Porto, 4200-319
Centro Hospitalar de Entre Douro e Vouga /ID# 166048
Santa Maria DA Feira, Porto District, 4520-211
Centro Hosp de Tondela-Viseu /ID# 166049
Viseu, 3504-509
Brazil7 sites
Upeclin Fmb - Unesp /Id# 157691
Botucatu, São Paulo, 18618-686
Hospital Nossa Senhora das Graças /ID# 157677
Curitiba, Paraná, 80810-040
Instituto Goiano de Gastroenterologia e Endoscopia Digestiva /ID# 157683
Goiânia, Goiás, 74535-170
Hospital de Clinicas de Porto Alegre /ID# 157670
Porto Alegre, Rio Grande do Sul, 90035-903
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto /ID# 157668
Ribeirão Preto, São Paulo, 14049-900
Faculdade de Medicina do ABC /ID# 163993
Santo André, La Spezia, 09060-870
Kaiser Clinica e Hospital Dia /ID# 157686
São José do Rio Preto, São Paulo, 15015-110
Israel6 sites
Soroka University Medical Center /ID# 171093
Beersheba, Southern District, 8443901
Rambam Health Care Campus /ID# 171096
Haifa, 3109601
Shaare Zedek Medical Center /ID# 163543
Jerusalem, Jerusalem, 91031
Hadassah Medical Center-Hebrew University /ID# 171092
Jerusalem, Jerusalem, 91120
Rabin Medical Center. /ID# 167402
Petah Tikva, 4941492
The Chaim Sheba Medical Center /ID# 211279
Ramat Gan, Tel Aviv, 5265601
New Zealand6 sites
Christchurch Hospital. /ID# 205337
Christchurch, Canterbury, 8011
Waikato Hospital /ID# 212788
Hamilton, Waikato Region, 3240
Hutt Hospital /ID# 212787
Lower Hutt, Wellington Region, 5010
Wellington Regional Hospital /ID# 205338
Newtown, Wellington Region, 6021
Dunedin Hospital /ID# 212791
Otago, Otago, 9016
Tauranga Hospital /ID# 212793
Tauranga South, Bay of Plenty, 3112
Romania6 sites
Sana Monitoring /Id# 224154
Bucharest, 011025
Fundeni Clinical Institute /ID# 171259
Bucharest, 022328
Fundeni Clinical Institute /ID# 224155
Bucharest, 022328
Clinica Gastro Med SRL /ID# 224156
Cluj-Napoca, Cluj, 400380
Cabinet Particular Policlinic Algomed /ID# 171260
Timișoara, 300002
Duplicate_Centrul Medical Tuculanu SRL /ID# 171263
Timișoara, 300168
Serbia6 sites
Clinical Hosp Center Zvezdara /ID# 200150
Belgrade, Beograd, 11000
University Clinical Center Serbia /ID# 200153
Belgrade, Beograd, 11000
Clinical Hospital Center Dr Dragisa Misovic - Dedinje /ID# 224927
Belgrade, Beograd, 11040
Clin Hosp Ctr Bezanijska Kosa /ID# 202060
Belgrade, Beograd, 11080
General Hospital Leskovac /ID# 224198
Leskovac, Jablanicki Okrug, 16000
Duplicate_Clinical Center Vojvodina /ID# 156876
Novi Sad, Vojvodina, 21000
South Africa6 sites
Farmovs (Pty) Ltd /Id# 207538
Bloemfontein, Free State, 9301
Allergy & Immunology (AIU) /ID# 171439
Cape Town, Western Cape, 7700
Dr JP Wright /ID# 171142
Cape Town, Western Cape, 7708
Private Practice Dr MN Rajabally /ID# 171141
Cape Town, Western Cape, 7800
Spoke Research Inc /ID# 229906
CAPE TOWN Milnerton, Western Cape, 7441
Clinresco Centers /ID# 239825
Johannesburg, Gauteng, 1619
Taiwan6 sites
Chung Shan Medical University Hospital /ID# 171426
Taichung, 402
China Medical University Hospital /ID# 160194
Taichung, 40447
Taichung Veterans General Hospital /ID# 171433
Taichung, 40705
Taipei Veterans General Hosp /ID# 171436
Taipei, 11217
National Taiwan University Hospital /ID# 162188
Taipei City, Taipei, 100
Linkou Chang Gung Memorial Hospital /ID# 222878
Taoyuan City, 333
Argentina5 sites
Cemic /Id# 167805
Ciudad Autonoma Buenos Aires, Buenos Aires, 1431
Gedyt /ID# 243424
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., 1115
Hospital Privado Universitario - Hospital Privado Centro Medico de Cordoba S.A. /ID# 167802
Córdoba, 5016
Hospital Provincial del Centenario /ID# 170896
Rosario, Santa Fe Province, 2000
Sanatorio 9 de Julio /ID# 167803
San Miguel de Tucumán, Tucumán Province, 4000
Austria5 sites
Duplicate_Medizinische Universitaet Graz /ID# 169052
Graz, Styria, 8010
Ordensklinikum Linz GmbH Barmherzige Schwestern /ID# 216043
Linz, Upper Austria, 4010
Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 200686
Salzburg, 5020
Duplicate_Universitaetsklinikum St.Poelten /ID# 169049
Sankt Pölten, Lower Austria, 3100
Medizinische Universitaet Wien /ID# 169051
Vienna, State of Vienna, 1090
Bulgaria5 sites
Umbal Kaspela /ID# 200795
Plovdiv, 4001
MHAT Hadzhi Dimitar /ID# 207947
Sliven, 8800
Duplicate_Second MHAT Sofia /ID# 200794
Sofia, 1202
UMHAT Sveti Ivan Rilski /ID# 210798
Sofia, 1431
Hospital Tsaritsa Yoanna /ID# 209978
Sofiya, Sofia, 1527
Croatia5 sites
Poliklinika Borzan d.o.o. /ID# 157595
Osijek, County of Osijek-Baranja, 31000
Klinicki Bolnicki Centar (KBC) Split /ID# 157596
Split, Split-Dalmatia County, 21000
Clinical Hospital Dubrava /ID# 157598
Zagreb, City of Zagreb, 10000
Klinicki bolnicki centar Zagreb /ID# 157594
Zagreb, City of Zagreb, 10000
Klinicki bolnicki centar Zagreb /ID# 201915
Zagreb, City of Zagreb, 10000
Czechia5 sites
Duplicate_Fakultni nemocnice u sv. Anny v Brne /ID# 239158
Brno, Brno-mesto, 656 91
SurGal Clinic /ID# 252300
Brno, South Moravian, 602 00
Nemocnice Ceske Budejovice a.s. /ID# 225228
České Budějovice, 370 01
Hepato-Gastroenterologie HK, s.r.o. /ID# 163389
Hradec Králové, 500 12
Fakultni Nemocnice Ostrava /ID# 225568
Ostrava, Ostrava-mesto, 708 52
Egypt5 sites
Alexandria University /ID# 226795
Alexandria, Alexandria Governorate, 21131
Alexandria University /ID# 226796
Alexandria, Alexandria Governorate, 21131
Duplicate_Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 201824
Alexandria, 21131
Air Force Specialized Hospital /ID# 170984
Cairo
National Liver Institute /ID# 171042
Menoufiya, Monufia Governorate, 35111
Ukraine5 sites
CNE Regional Clinical Hospital of Ivano-Frankivsk RC /ID# 203366
Ivano-Frankivsk, 76018
Municipal Nonprofit Enterprise Kherson city clinical hospital n.a. Y.Y. Karabel /ID# 224349
Kherson, 73000
Medical Center OK Clinic LLC, International Institute of Clinical Research /ID# 205484
Kyiv, 02091
CNPE of Kyiv Regional Council Kyiv Regional Hospital /ID# 224344
Kyiv, 04073
Medical center of the private enterprise Sygma /ID# 224347
Kyiv, 04116
Chile4 sites
Hospital Guillermo Grant Benavente de Concepción /ID# 210762
Concepción, Biobio, 4070038
Complejo Asistencial Dr. Sotero del Rio /ID# 169386
Santiago, Santiago Metropolitan, 8207257
Hospital Las Higueras /ID# 167094
Talcahuano, Biobio, 1740000
Duplicate_Servicio de Salud Araucanía Norte Hospital Victoria /ID# 213152
Victoria, Araucania, 4720843
Denmark4 sites
Bispebjerg and Frederiksberg Hospital /ID# 208953
Copenhagen NV, Capital Region, 2400
Kobenhavns Universitet - Hvidovre Hospital (HH) /ID# 205093
Hvidovre, Capital Region, 2650
Duplicate_Odense Universitets Hospital /ID# 209502
Odense C, Region Syddanmark, 5000
Duplicate_Sjællands Universitetshospital /ID# 200073
Roskilde, Region Sjælland, 4000
Slovakia4 sites
Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica /ID# 164348
Banská Bystrica, Banská Bystrica Region, 975 17
KM Management, spol. s.r.o. /ID# 206603
Nitra, Nitra Region, 949 01
Fakultna nemocnica s poliklinikou Nove Zamky /ID# 224100
Nové Zámky, Nitra Region, 940 34
Gastro I., s.r.o. /ID# 164345
Prešov, Presov, 080 01
Colombia3 sites
Coorp Hosp Juan Ciudad Sede Hospital Universitario Mayor Mederi /ID# 158736
Bogota DC, Cundinamarca, 111221
Fundación Hospitalaria San Vicente de Paul /ID# 171488
Medellín, Antioquia, 50010
Imat Oncomedica /ID# 207041
Montería, Departamento de Córdoba, 230018
Mexico3 sites
JM Research SC /ID# 206518
Cuernavaca, Morelos, 62290
Health Pharma Professional Research S.A de C.V /ID# 206516
Del. Benito Juárez, 03810
Unidad de Atencion Medica e Investigacion en Salud /ID# 206515
Mérida, Yucatán, 97000
Sweden3 sites
Alingsas lasarett /ID# 202075
Alingsås, Västra Götaland County, 441 33
Sahlgrenska University Hospital Molndal /ID# 202841
Mölndal, Västra Götaland County, 431 80
Danderyds sjukhus AB /ID# 202036
Stockholm, 182 88
Latvia2 sites
VCA Polyclinic Aura /ID# 160204
Riga, 1035
Pauls Stradins Clinical University Hospital /ID# 160205
Riga, LV-1002
Lithuania2 sites
Hospital of Lithuanian University of Health Sciences Kaunas Clinics /ID# 201142
Kaunas, 50161
Vilnius University Hospital Santaros Klinikos /ID# 201144
Vilnius, 08661
Netherlands2 sites
Amsterdam UMC, locatie AMC /ID# 157965
Amsterdam, North Holland, 1105 AZ
Elisabeth Tweesteden Ziekenhuis /ID# 163738
Tilburg, North Brabant, 5022 GC
Puerto Rico2 sites
Ponce Medical School Foundation /ID# 222825
Ponce, 00716-0377
VA Caribbean Healthcare System /ID# 222779
San Juan, 00921-3201
Switzerland2 sites
Inselspital, Universitaetsspital Bern /ID# 202909
Bern, 3010
University Hospital Zurich /ID# 202908
Zurich, Canton of Zurich, 8091
Singapore1 site
Mount Elizabeth Hospital /ID# 206563
Singapore, Central Singapore, 228510
About this study
Official title: A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis
The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC.
This study consists of three sub-studies and a Continuous Treatment Extension (CTE): Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for participants who completed Substudy 1 or 2, or participants who responded to induction treatment in Study M16-067 with no final endoscopy due to the Covid-19 pandemic or due to the geopolitical conflict in Ukraine and surrounding impacted regions. The CTE is an open-label extension for Substudy 3 completers to ensure continuous treatment with risankizumab until such time that risankizumab becomes commercially available and/or the subject can access treatment locally.
- Conditions
- Ulcerative Colitis (UC)
- Being tested
- risankizumab, placebo for risankizumab
- Keywords
- ABBV-066, BI 655066
- Medical subject headings
- Colitis, Ulcerative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
risankizumabDrug
Also called ABBV-066, BI 655066, SKYRIZI
subcutaneous (SC) injection
placebo for risankizumabDrug
subcutaneous (SC) injection
| Study group | Role | What they receive |
|---|---|---|
| Substudy 1: Double-blind Placebo | Placebo comparator | Participants randomized to receive placebo for risankizumab administered by subcutaneous (SC) injection. Receives: Drug: placebo for risankizumab |
| Substudy 1: Double-blind Risankizumab Dose 1 | Experimental | Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection. Receives: Drug: risankizumab |
| Substudy 1: Double-blind Risankizumab Dose 2 | Experimental | Participants randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection. Receives: Drug: risankizumab |
| Substudy 2: Open-label (OL) Clinical Assessment Risankizumab | Experimental | Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection. Receives: Drug: risankizumab |
| Substudy 2: OL Therapeutic Drug Monitoring Risankizumab | Experimental | Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection. Receives: Drug: risankizumab |
| Substudy 3: OL Extension Risankizumab | Experimental | Participants who completed Sub-study 1 or 2 receive open-label risankizumab in Sub-study 3. Receives: Drug: risankizumab |
| OL Continuous Treatment Extension - Dose 1 | Experimental | Participants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 without receiving risankizumab rescue therapy in any sub-study will receive risankizumab Dose 1 administered by subcutaneous (SC) injection. Receives: Drug: risankizumab |
| OL Continuous Treatment Extension - Dose 2 | Experimental | Participants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 and received risankizumab rescue therapy in any sub-study will receive risankizumab Dose 2 administered by subcutaneous (SC) injection. Receives: Drug: risankizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sub-Study 1: Percentage of Participants Achieving Clinical Remission per Adapted Mayo Score
Clinical remission per Adapted Mayo Score.
Measured: Week 52
Percentage of Participants with Adverse Events (AE)
An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Measured: Up to Week 300
Secondary outcomes (17)
Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement
Endoscopic improvement per endoscopy subscore.
Measured: Week 52
Sub-Study 1: Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement
Percentage of participants achieving histologic-endoscopic mucosal improvement.
Measured: Week 52
Sub-Study 1: Percentage of Participants Achieving Endoscopic Remission
Endoscopic remission per endoscopy subscore.
Measured: Week 52
Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score in Participants with no Corticosteroid Use for 90 days
Clinical remission per Adapted Mayo Score.
Measured: Week 52
Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score in Participants with a Clinical Remission at Week 0
Clinical remission per Adapted Mayo Score.
Measured: Week 52
Sub-Study 1: Percentage of Participants Achieving No Bowel Urgency
Percentage of participants achieving no bowel urgency.
Measured: Week 52
Sub-Study 1: Percentage of Participants Achieving No Abdominal Pain
Percentage of participants achieving no abdominal pain.
Measured: Week 52
Sub-Study 1: Percentage of Participants Achieving Histologic-Endoscopic Mucosal Remission
Percentage of participants achieving histologic-endoscopic mucosal remission per endoscopy subscore.
Measured: Week 52
Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement in Participants with Endoscopic Improvement at Week 0
Endoscopic improvement per endoscopy subscore.
Measured: Week 52
Sub-Study 1: Percentage of Participants Achieving Clinical Response per Adapted Mayo Score
Clinical response per Adapted Mayo Score.
Measured: Week 52
Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
The FACIT-Fatigue is a validated tool that measures an individual's level of fatigue during their usual daily activities over the past week.
Measured: Week 0 to Week 52
Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)
The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease.
Measured: Baseline (Week 0) to Week 52
Sub-Study 1: Percentage of Participants Achieving No Nocturnal Bowel Movements
Percentage of participants achieving no nocturnal bowel movements.
Measured: Week 52
Sub-Study 1: Percentage of Participants Achieving No Tenesmus
Percentage of participants achieving no tenesmus.
Measured: Week 52
Sub-Study 1: Change in Number of Fecal Incontinence Episodes per Week
Change in number of fecal incontinence episodes per week.
Measured: Baseline (Week 0) to Week 52
Sub-Study 1: Change in Number of Days per Week with Sleep Interrupted due to UC Symptoms
Change in number of days per week with sleep interrupted due to UC symptoms.
Measured: Baseline (Week 0) to Week 52
Sub-Study 1: Percentage of Participants with Exposure Adjusted Occurrence of Ulcerative Colitis (UC) Related Hospitalization
Participants with an exposure adjusted occurrence of UC event that results in admission to the hospital.
Measured: Through Week 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2018
- Study start28 Aug 2018
- Primary completionSep 2028 (estimated)
- Study completionFeb 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Ulcerative Colitis (UC)Studies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 1,242 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03398135
- Sponsor's protocol ID
- M16-066
- Other IDs
- 2023-506994-36-00, 2023
- Acronym
- COMMAND
- Status last verified
- Jan 2026
- First submitted
- 8 Jan 2018
- Last updated
- 20 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Publications
Panaccione R, Melmed GY, Drobne D, Kaur M, Danese S, Hisamatsu T, Kalabic J, Chen S, Cheng L, Duan WR, Shah S, Louis E. Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment. Clin Gastroenterol Hepatol. 2026 May;24(5):1424-1433. doi: 10.1016/j.cgh.2025.09.007. Epub 2025 Sep 13.
PubMed 40953785Reinisch W, Loftus EV Jr, Schreiber S, Rubin DT, Louis E, Hecht PM, Barrachina EM, Kalabic J, Vladea R, Sharma D, Duan WR, Zhang Y, Panaccione R. Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. J Crohns Colitis. 2025 Apr 4;19(4):jjaf025. doi: 10.1093/ecco-jcc/jjaf025.
PubMed 40168091Panaccione R, Louis E, Colombel JF, D'Haens G, Peyrin-Biroulet L, Dubinsky M, Takeuchi K, Rubin DT, Kalabic J, Chien KB, Chen S, Cheng L, Zhang Y, Duan WR, Vladea R, Hecht PM, Morisset P, Schreiber S, Ferrante M. Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. J Crohns Colitis. 2025 Jan 11;19(1):jjaf005. doi: 10.1093/ecco-jcc/jjaf005.
PubMed 39804294Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414.
PubMed 39037800Thakre N, Goebel A, Winzenborg I, Suleiman AA, D'Cunha R, Mensing S, Liu W, Pang Y. Population Pharmacokinetic and Exposure-Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis. Clin Pharmacol Ther. 2024 Sep;116(3):847-857. doi: 10.1002/cpt.3330. Epub 2024 Jun 11.
PubMed 38863178
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis
- ClinicalTrials.gov ID
- NCT03398135
- Acronym / sponsor ID
- COMMAND / M16-066
- Conditions
- Ulcerative Colitis (UC)
- Keywords
- ABBV-066, BI 655066
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,242 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 28 Aug 2018 (actual)
- Primary completion
- Sep 2028 (estimated)
- Study completion
- Feb 2029 (estimated)
- First posted
- 12 Jan 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC.
This study consists of three sub-studies and a Continuous Treatment Extension (CTE): Substudy 1 is a 52-week, randomized, double-blind, placebo-controlled maintenance study; Substudy 2 is 52-week, randomized, exploratory maintenance study; and Substudy 3 is an open-label long-term extension study for participants who completed Substudy 1 or 2, or participants who responded to induction treatment in Study M16-067 with no final endoscopy due to the Covid-19 pandemic or due to the geopolitical conflict in Ukraine and surrounding impacted regions. The CTE is an open-label extension for Substudy 3 completers to ensure continuous treatment with risankizumab until such time that risankizumab becomes commercially available and/or the subject can access treatment locally.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 8
| Arm | Type | Receives |
|---|---|---|
| Substudy 1: Double-blind Placebo | Placebo comparator | Drug: placebo for risankizumabParticipants randomized to receive placebo for risankizumab administered by subcutaneous (SC) injection. |
| Substudy 1: Double-blind Risankizumab Dose 1 | Experimental | Drug: risankizumabParticipants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection. |
| Substudy 1: Double-blind Risankizumab Dose 2 | Experimental | Drug: risankizumabParticipants randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection. |
| Substudy 2: Open-label (OL) Clinical Assessment Risankizumab | Experimental | Drug: risankizumabParticipants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection. |
| Substudy 2: OL Therapeutic Drug Monitoring Risankizumab | Experimental | Drug: risankizumabParticipants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection. |
| Substudy 3: OL Extension Risankizumab | Experimental | Drug: risankizumabParticipants who completed Sub-study 1 or 2 receive open-label risankizumab in Sub-study 3. |
| OL Continuous Treatment Extension - Dose 1 | Experimental | Drug: risankizumabParticipants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 without receiving risankizumab rescue therapy in any sub-study will receive risankizumab Dose 1 administered by subcutaneous (SC) injection. |
| OL Continuous Treatment Extension - Dose 2 | Experimental | Drug: risankizumabParticipants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 and received risankizumab rescue therapy in any sub-study will receive risankizumab Dose 2 administered by subcutaneous (SC) injection. |
Who may qualify
- Ages
- 16 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Participants who have completed Study M16-067 and have achieved clinical response as defined in the protocol.
Key exclusion criteria (3 listed)
- Participants who have a known hypersensitivity to risankizumab or the excipients of any of the study drugs or the ingredients of chinese hamster ovary (CHO) or had an adverse event (AE) during Studies M16-067 that in the Investigator's judgment makes the participant unsuitable for this study.
- Participant is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
- Participant is not in compliance with prior and concomitant medication requirements throughout Studies M16-067.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| risankizumabAlso: ABBV-066, BI 655066, SKYRIZIsubcutaneous (SC) injection | Drug | OL Continuous Treatment Extension - Dose 1, OL Continuous Treatment Extension - Dose 2, Substudy 1: Double-blind Risankizumab Dose 1, Substudy 1: Double-blind Risankizumab Dose 2, Substudy 2: OL Therapeutic Drug Monitoring Risankizumab, Substudy 2: Open-label (OL) Clinical Assessment Risankizumab, Substudy 3: OL Extension Risankizumab |
| placebo for risankizumabsubcutaneous (SC) injection | Drug | Substudy 1: Double-blind Placebo |
Primary outcome
Sub-Study 1: Percentage of Participants Achieving Clinical Remission per Adapted Mayo Score
Time frame: Week 52
Clinical remission per Adapted Mayo Score.
Percentage of Participants with Adverse Events (AE)
Time frame: Up to Week 300
An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
17 secondary outcomes
Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving Endoscopic Remission
Time frame: Week 52
Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score in Participants with no Corticosteroid Use for 90 days
Time frame: Week 52
Sub-Study 1: Percentage of Participants with Clinical Remission per Adapted Mayo Score in Participants with a Clinical Remission at Week 0
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving No Bowel Urgency
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving No Abdominal Pain
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving Histologic-Endoscopic Mucosal Remission
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement in Participants with Endoscopic Improvement at Week 0
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving Clinical Response per Adapted Mayo Score
Time frame: Week 52
Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
Time frame: Week 0 to Week 52
Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)
Time frame: Baseline (Week 0) to Week 52
Sub-Study 1: Percentage of Participants Achieving No Nocturnal Bowel Movements
Time frame: Week 52
Sub-Study 1: Percentage of Participants Achieving No Tenesmus
Time frame: Week 52
Sub-Study 1: Change in Number of Fecal Incontinence Episodes per Week
Time frame: Baseline (Week 0) to Week 52
Sub-Study 1: Change in Number of Days per Week with Sleep Interrupted due to UC Symptoms
Time frame: Baseline (Week 0) to Week 52
Sub-Study 1: Percentage of Participants with Exposure Adjusted Occurrence of Ulcerative Colitis (UC) Related Hospitalization
Time frame: Through Week 52
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
- Derived from this study: PubMed 40953785Panaccione R, Melmed GY, Drobne D, Kaur M, Danese S, Hisamatsu T, Kalabic J, Chen S, Cheng L, Duan WR, Shah S, Louis E. Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment. Clin Gastroenterol Hepatol. 2026 May;24(5):1424-1433. doi: 10.1016/j.cgh.2025.09.007. Epub 2025 Sep 13.
- Derived from this study: PubMed 40168091Reinisch W, Loftus EV Jr, Schreiber S, Rubin DT, Louis E, Hecht PM, Barrachina EM, Kalabic J, Vladea R, Sharma D, Duan WR, Zhang Y, Panaccione R. Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. J Crohns Colitis. 2025 Apr 4;19(4):jjaf025. doi: 10.1093/ecco-jcc/jjaf025.
- Derived from this study: PubMed 39804294Panaccione R, Louis E, Colombel JF, D'Haens G, Peyrin-Biroulet L, Dubinsky M, Takeuchi K, Rubin DT, Kalabic J, Chien KB, Chen S, Cheng L, Zhang Y, Duan WR, Vladea R, Hecht PM, Morisset P, Schreiber S, Ferrante M. Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. J Crohns Colitis. 2025 Jan 11;19(1):jjaf005. doi: 10.1093/ecco-jcc/jjaf005.
- Derived from this study: PubMed 39037800Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414.
- Derived from this study: PubMed 38863178Thakre N, Goebel A, Winzenborg I, Suleiman AA, D'Cunha R, Mensing S, Liu W, Pang Y. Population Pharmacokinetic and Exposure-Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis. Clin Pharmacol Ther. 2024 Sep;116(3):847-857. doi: 10.1002/cpt.3330. Epub 2024 Jun 11.
- Individual participant dataSharing planned: Yes. AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Related trials for Ulcerative Colitis (UC)
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
Not yet recruitingObservational study
Non-Invasive Biomarker Monitoring in UC on Biologics
Ulcerative Colitis
RecruitingPhase 2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
RecruitingPhase 1/2
Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
RecruitingPhase 1/2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Ulcerative Colitis (UC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ABBVIE INC. study director
AbbVie
426 sites in 43 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing risankizumab in people with Ulcerative Colitis (UC), run by AbbVie at 426 sites in 43 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 426 sites in United States, Japan, China, Germany, Russia and 38 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sub-Study 1: Percentage of Participants Achieving Clinical Remission per Adapted Mayo Score (time frame: Week 52). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03398135, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026.